Fasenra Archives -

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment

FDA says no to AZ’s Fasenra for nasal polyp indication

https://pharmaphorum.com/news/fda-says-no-to-azs-fasenra-for-nasal-polyp-indication/

Sanofi/Regeneron on notice as FDA reviews GSK’s Nucala for nasal polyps

Phil Taylor AstraZeneca, Dupixent, Fasenra, fda, GlaxoSmithKline, inflammatory diseases, nasal polyps, Nucala, Regeneron, Sanofi 0 Comment

Sanofi and Regeneron’s Dupixent has had the US market for the treatment of chronic rhinosinusitis with nasal polyps

Sanofi/Regeneron on notice as FDA reviews GSK’s Nucala for nasal polyps

https://pharmaphorum.com/news/dupixent-on-notice-as-fda-reviews-gsks-nucala-for-nasal-polyps/

Market Access/ News/ News

EU clears GSK’s asthma drug Nucala in patient-friendly format

Phil Taylor AstraZeneca, Fasenra, GlaxoSmithKline, Nucala, respiratory, severe asthma, Teva 0 Comment

With competition heating up in the severe asthma category, GlaxoSmithKline has a new EU approval that it hopes

EU clears GSK’s asthma drug Nucala in patient-friendly format

https://pharmaphorum.com/news/eu-clears-gsks-asthma-drug-nucala-in-patient-friendly-format/

Market Access/ News/ News

NICE broadens approval for AstraZeneca’s severe asthma drug

George Underwood asthma, AstraZeneca, Fasenra 0 Comment

AstraZeneca’s Fasenra (benralizumab) has seen its fortunes reverse after NICE approved the drug for severe eosinophilic asthma –

NICE broadens approval for AstraZeneca’s severe asthma drug

https://pharmaphorum.com/news/nice-broadens-approval-for-astrazenecas-severe-asthma-drug/

News/ News/ R&D/ Top stories

AstraZeneca’s respiratory biologic fails again in COPD

Linda Banks AZ, COPD, Fasenra, MedImmune, respiratory biologic, respiratory disease 0 Comment

AstraZeneca (AZ) and MedImmune, have announced that the latest trial of Fasenra (benralizumab) in patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD) did not provide a statistically-significant reduction in exacerbations.

AstraZeneca’s respiratory biologic fails again in COPD

https://pharmaphorum.com/news/astrazenecas-respiratory-biologic-copd/

Trending

Fasenra

Login